Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease.

(Ghassan K. Abou-Alfa et al. – The New England Journal of Medicine, 5 July 2018)

Read more